Belgium's Ablynx, which is developing a pipeline of Nanobody-based therapeutics, is planning to go public. There's no word on how big the offering is intended to be, but the biotech has raised close to $100 million in venture funds to develop tiny antibody-based therapies. Nanobodies, explains Ablynx, are a class of therapeutic proteins based on single-domain antibody fragments which have been generated against more than 100 different disease targets.
- check out the release on the IPO plans
Read more on: Ablynx | Nanotechnology